• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Needham reiterated coverage on Immuneering Corporation with a new price target

    3/15/24 7:50:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously
    Get the next $IMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    More analyst ratings

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Zeskind Benjamin J. bought $50,144 worth of shares (21,000 units at $2.39), increasing direct ownership by 0.92% to 2,302,852 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      6/20/25 9:09:33 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schall Thomas J. bought $89,278 worth of shares (40,485 units at $2.21), increasing direct ownership by 1,396% to 43,385 units (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      6/18/25 9:11:22 AM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schall Thomas J. bought $7,385 worth of shares (2,900 units at $2.55) (SEC Form 4)

      4 - Immuneering Corp (0001790340) (Issuer)

      3/25/24 4:03:33 PM ET
      $IMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care